Understanding the different approaches to psoriasis care

Psoriasis is often called a skin condition, which is a bit like calling a house fire a smoke problem. It is an immune disease that happens to show up on the skin, and it affects roughly 2% of the UK population.

Estimates run from 1.1 million people to about 1.8 million once cases that never get diagnosed are taken into account. Most are managed by a GP, never see a dermatologist and are told very little about what sits further up the treatment ladder.

Creams do more work than they get credit for

The vast majority of psoriasis in Britain is mild to moderate, and plenty of it never leaves the topical stage. The standard prescription pairs calcipotriol (a vitamin D analogue) with a strong steroid such as betamethasone dipropionate, applied once daily.

Whether it works usually comes down to unglamorous details. Used properly for four to eight weeks, it tends to flatten plaques and settle scaling. Used in fits and starts, it can look like a dud.

There is also a cost angle that is easily forgotten. At £9.90 per item in England, a scalp preparation plus a body ointment plus an emollient adds up quickly, which is exactly the situation a £114.50 annual prepayment certificate is designed for. (Prescriptions are free in Scotland, Wales and Northern Ireland.)

Light therapy sits in the middle

When creams stop being enough, the next step is usually ultraviolet light. The treatment for psoriasis shifts here from something done at the bathroom sink to a supervised course with a set schedule and a dose that is adjusted along the way.

Narrowband UVB at 311 nm has been standard in NHS dermatology departments for decades: two or three sessions a week, typically across 8 to 12 weeks. Pooled clinical data report that roughly 70% of patients reach PASI 75 (shorthand for a 75% drop in severity score), with steroid cream use reported to fall alongside it.

Guidance such as the NICE psoriasis guideline places phototherapy between topical and systemic therapy. The catch is geography. Three trips a week to a hospital cabinet for two months is a serious commitment for anyone working full time or living an hour from the nearest unit, which is why supervised home phototherapy has gained ground in the UK.

Burning and dryness are the usual side effects, and the clinical team keeps a running record of each patient’s lifetime UV exposure.

When something systemic is needed

Severe or stubborn cases move on to drugs that work throughout the body. Methotrexate is the first conventional option under NICE guidance, with ciclosporin used for quick short-term control and acitretin kept for particular presentations. All three require regular blood monitoring, so none of them is prescribed casually.

Then biologics arrived and changed the picture. These block specific signals in the inflammatory chain: TNF-alpha, interleukin-17 (secukinumab) and interleukin-23 (guselkumab).

Completely clear skin was once considered unrealistic and is now a routine endpoint in clinical trials, although results vary between patients. Getting a biologic on the NHS is another matter. Most of the relevant technology appraisals require a PASI score of 10 or more plus a DLQI above 10, and evidence that the standard systemic drugs have already failed or cannot be tolerated.

The skin is only part of the story

Around 30% of people with psoriasis go on to develop psoriatic arthritis, and joint damage can become permanent if it is not caught early. Good practice now means clinicians ask about joints, not just elbows.

The list does not end there. Cardiovascular disease, metabolic syndrome, inflammatory bowel disease and depression all appear more often in this group, which is why losing weight and stopping smoking are not throwaway advice. Both are reported to measurably affect how well treatment works.

There is a social cost too. WHO’s 2016 global report identified stigma and misdiagnosis as major parts of the burden, alongside the physical symptoms. Many patients say the staring in a changing room bothers them more than the itching does.

Where this is heading

The most significant shift is not a single new drug. It is the gradual move towards matching treatment intensity to the individual rather than moving everybody up the same ladder, one rung at a time.

For now the advice remains unglamorous. Push for a proper diagnosis, use treatments as directed, mention joint pain to a GP before it becomes a problem and treat any plan as something to revisit rather than a life sentence.

This article is general information, not medical advice. Treatment decisions should be made with a qualified dermatologist or GP.

The editorial unit